Abdom Radiol (NY). 2024 Oct;49(10):3325-3336. doi: 10.1007/s00261-024-04318-4.Epub 2024 May 9.

Vinicius de Padua V Alves ¹, Neeraja Mahalingam ², Jean A Tkach ^2 3, Alexander J Towbin ^2 3, Rebecca Imbus ², Lee A Denson ^4 5, Jonathan R Dillman ^2 3

Author information

¹Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. vinpvalves@gmail.com.

²Department of Radiology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.

³Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

⁴Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

⁵Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital, Cincinnati, OH, USA.

Abstract

Background: MRI diffusion-weighted imaging (DWI) is commonly used in MR enterography protocols for assessment of intestinal inflammation in patients with Crohn's disease. The intravoxel incoherent motion (IVIM) approach to DWI has been proposed as a more objective approach, providing quantitative parameters that reflect water diffusivity (D), blood flow (D*), and perfusion fraction (f).

Purpose: We aimed to determine if DWI-IVIM metrics from the terminal ileum in patients with newly diagnosed Crohn's disease differ from healthy participants and change in response to biologic medical therapy.

Methods: In this prospective case-control study, 20 consecutive pediatric patients (mean age = 14 years ± 2 [SD]; eight females) with newly diagnosed ileal Crohn's disease and 15 pediatric healthy participants (mean age = 18 years ± 4 [SD]; eight females) underwent research MRI examinations of the small bowel between 12/2018 and 10/2021. Participants with Crohn's disease underwent MR studies at baseline, 6 weeks, and 6 months following initiation of anti-TNF-alpha therapy, whereas control participants underwent one research MRI examination. The MRI protocol included a DWI-IVIM sequence with nine b-values and the IVIM parameters (D, D*, and f) were extracted. Unpaired t-tests and mixed-effects models were used for analyses.

Results: Mean IVIM D (P < 0.001), D* (P = 0.004), and f (P = 0.001) metrics were lower for Crohn's patients at the time of diagnosis compared to healthy participants. Mean IVIM f value increased over time in response to medical therapy (mean f at baseline, 22% ± 6%; 6 weeks, 25% ± 7%; 6 months, 29% ± 10%; P = 0.016). Mean IVIM D* value increased over time in response to treatment (mean D* at baseline, 10.9 ± 3.0 × 10^-3 mm²/s; 6 weeks, 11.8 ± 2.8 × 10^-3 mm²/s; 6 months, 13.3 ± 3.3 × 10^-3 mm²/s; P = 0.047), while there was no significant change in mean IVIM D value (P = 0.10).

Conclusion: MRI DWI-IVIM metrics in patients with ileal Crohn's disease change over time in response to biological therapy and help discriminate these patients from healthy participants.